CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

FBI Raids Bristol Myers Squibb

Feds Open Probe Into Deal to Delay Plavix Competitor





July 28, 2006

Bristol-Myers Squibb
FBI Raids Bristol Myers Squibb
FDA Approves Generic Version Of Pravachol
Drug Companies Reduce Discounts
BuSpar Checks Issued
States Sue Bristol Over BuSpar

FBI agents raided the office of Bristol-Myers Squibb Co. CEO Peter Dolan, as the Justice Department opened a criminal investigation into the company's deal to delay the launch of a generic version of its best-selling drug, Plavix.

The company is allegedly paying a Canadian company not to produce a a drug similar to Plavix. BMS confirms that it is the target of a Justice Department probe, which will determine whether laws have been broken. It provided no other details.

The unique circumstances revolve around the patents that BMS and its partner Sanofi hold on Plavix. Canadian drug maker Apotex is challenging those patents and was poised to launch its copycat version of Plavix in the next few months.

Earlier this year BMS and Apotex reportedly agreed on a deal for Apotex to suspend its legal challenge to the Plavix patents.

In return, it would receive permission to launch its generic version of Plavix a few months before the patents expired. For the agreement, Apotex would receive a cash payment from BMS.

At first the Federal Trade Commission objected to the terms, forcing the two sides to renegotiate portions of the agreement. Consumer advocates, however, were outraged at the deal, saying it's illegal and will end up keeping drug prices high.

The Justice Department investigation will determine whether the deal, is in fact, legal or not.

If it finds that it is not, industry analysts say it will be a significant blow against large drug makers, who have seen small generic competitors make significant legal inroads against patent protections in recent years.

These same analysts say, however, that striking down the deal would continue a trend that has resulted in steadily lower drug prices for insurers and government.

Plavix, a blood-thinner, is BMS's most profitable drug. It produced $2.1 billion in revenue in the first six months of this year.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

August 30 2008

Recent Recalls & Safety Alerts



FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.







Back to the top |

Advertisement


Home | Complaint Form | News | Recalls | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds |


Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.